BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 17097117)

  • 1. The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens.
    Rahman S; Neugebauer NM; Zhang Z; Crooks PA; Dwoskin LP; Bardo MT
    Neuropharmacology; 2007 Mar; 52(3):755-63. PubMed ID: 17097117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Region-specific effects of N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide on nicotine-induced increase in extracellular dopamine in vivo.
    Rahman S; Zhang Z; Papke RL; Crooks PA; Dwoskin LP; Bardo MT
    Br J Pharmacol; 2008 Feb; 153(4):792-804. PubMed ID: 18059317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release.
    Smith AM; Pivavarchyk M; Wooters TE; Zhang Z; Zheng G; McIntosh JM; Crooks PA; Bardo MT; Dwoskin LP
    Biochem Pharmacol; 2010 Aug; 80(3):402-9. PubMed ID: 20346923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens.
    Rahman S; Neugebauer NM; Zhang Z; Crooks PA; Dwoskin LP; Bardo MT
    Eur J Pharmacol; 2008 Dec; 601(1-3):103-5. PubMed ID: 19000671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [(3)H]norepinephrine overflow from rat hippocampal slices.
    Smith AM; Dhawan GK; Zhang Z; Siripurapu KB; Crooks PA; Dwoskin LP
    Biochem Pharmacol; 2009 Oct; 78(7):889-97. PubMed ID: 19631612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats.
    Neugebauer NM; Zhang Z; Crooks PA; Dwoskin LP; Bardo MT
    Psychopharmacology (Berl); 2006 Mar; 184(3-4):426-34. PubMed ID: 16220336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of nitric oxide synthase inhibitor and NMDA receptor antagonist on the development of nicotine sensitization of nucleus accumbens dopamine release: an in vivo microdialysis study.
    Hong SK; Jung IS; Bang SA; Kim SE
    Neurosci Lett; 2006 Dec; 409(3):220-3. PubMed ID: 17046158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective stimulation of serotonin2c receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration.
    Di Matteo V; Pierucci M; Esposito E
    J Neurochem; 2004 Apr; 89(2):418-29. PubMed ID: 15056285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N,N'-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity.
    Dwoskin LP; Wooters TE; Sumithran SP; Siripurapu KB; Joyce BM; Lockman PR; Manda VK; Ayers JT; Zhang Z; Deaciuc AG; McIntosh JM; Crooks PA; Bardo MT
    J Pharmacol Exp Ther; 2008 Aug; 326(2):563-76. PubMed ID: 18460644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a novel neurotensin analog, NT69L, on nicotine-induced alterations in monoamine levels in rat brain.
    Liang Y; Boules M; Shaw AM; Williams K; Fredrickson P; Richelson E
    Brain Res; 2008 Sep; 1231():6-15. PubMed ID: 18687313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined effects of systemic alcohol and nicotine on dopamine release in the nucleus accumbens shell.
    Tizabi Y; Bai L; Copeland RL; Taylor RE
    Alcohol Alcohol; 2007; 42(5):413-6. PubMed ID: 17686828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic nicotine stimulates dopamine release in nucleus accumbens: re-evaluation of the role of N-methyl-D-aspartate receptors in the ventral tegmental area.
    Fu Y; Matta SG; Gao W; Brower VG; Sharp BM
    J Pharmacol Exp Ther; 2000 Aug; 294(2):458-65. PubMed ID: 10900219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse.
    Wooters TE; Smith AM; Pivavarchyk M; Siripurapu KB; McIntosh JM; Zhang Z; Crooks PA; Bardo MT; Dwoskin LP
    Br J Pharmacol; 2011 May; 163(2):346-57. PubMed ID: 21232049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD).
    Dwoskin LP; Joyce BM; Zheng G; Neugebauer NM; Manda VK; Lockman P; Papke RL; Bardo MT; Crooks PA
    Biochem Pharmacol; 2007 Oct; 74(8):1271-82. PubMed ID: 17727820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered extracellular levels of DOPAC and HVA in the rat nucleus accumbens shell in response to sub-chronic nandrolone administration and a subsequent amphetamine challenge.
    Birgner C; Kindlundh-Högberg AM; Nyberg F; Bergström L
    Neurosci Lett; 2007 Jan; 412(2):168-72. PubMed ID: 17123707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute and subacute effects of risperidone and cocaine on accumbens dopamine and serotonin release using in vivo microvoltammetry on line with open-field behavior.
    Broderick PA; Rahni DN; Zhou Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):1037-54. PubMed ID: 14499322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NR2B-selective N-methyl-D-aspartate receptor antagonist Ro 25-6981 [(+/-)-(R*,S*)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine propanol] potentiates the effect of nicotine on locomotor activity and dopamine release in the nucleus accumbens.
    Kosowski AR; Liljequist S
    J Pharmacol Exp Ther; 2004 Nov; 311(2):560-7. PubMed ID: 15256539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents.
    Dwoskin LP; Sumithran SP; Zhu J; Deaciuc AG; Ayers JT; Crooks PA
    Bioorg Med Chem Lett; 2004 Apr; 14(8):1863-7. PubMed ID: 15050617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iptakalim inhibits nicotine-induced enhancement of extracellular dopamine and glutamate levels in the nucleus accumbens of rats.
    Liu Q; Li Z; Ding JH; Liu SY; Wu J; Hu G
    Brain Res; 2006 Apr; 1085(1):138-43. PubMed ID: 16647046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotine administration significantly alters accumbal dopamine in the adult but not in the adolescent rat.
    Badanich KA; Kirsteina CL
    Ann N Y Acad Sci; 2004 Jun; 1021():410-7. PubMed ID: 15251919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.